Humana Bumps Up FY22 Profit Outlook, Stops Factoring COVID-19 Impact In Guidance, Shares Jump

  • American health insurance company Humana Inc HUM revealed an adjusted EPS target for FY 2025 of $37, representing a 14% compounded annual growth rate over the company's updated FY 2022 adjusted EPS outlook.
  • The company expects to grow enterprise earnings by approximately 10% per year before factoring in an additional 1% - 2% of anticipated earnings growth driven by the company's commitment to improving operating leverage by approximately 20 basis points annually on a business mix adjusted basis. 
  • In addition, Humana expects capital deployment to contribute approximately 2% to annual EPS growth.
  • Humana has also increased its GAAP and adjusted EPS guidance for FY22 to approximately $23.08 from its previous estimate of approximately $20.30 and adjusted EPS to approximately $25 versus approximately $24.75 expected earlier.
  • The updated adjusted guidance reflects 21% growth compared to FY 2021 adjusted EPS results, driven by the continued lower-than-expected medical cost trends in the company's Medicare Advantage and Medicaid businesses and the lack of a COVID-19 headwind materializing.
  • The company no longer deems it necessary to hold a discrete COVID-19 headwind in its full-year guide.
  • Humana will release its Q3 FY22 earnings on November 2.
  • Price Action: HUM shares are up 6.98% at $490.90 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: Large CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!